Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Safety Initiatives Could Suffer Under Trump's Budget Proposal

Executive Summary

User fee-heavy budget proposes appears to tie into Trump's broader deregulatory strategy; CDER and CBER would have to make cuts to non-user fee safety initiatives.


Related Content

Trump's Budget Surprise: FDA Gets 13% Increase
Trump's Budget Surprise: FDA Gains 13% Increase
OMB's Grogan Talks Drug Pricing And Taking On 'Sacred Cows'
FDA's Orphan Designation Backlog Plan Focuses On Efficiency, Not Staff
Breakthrough-Style Program For ANDAs Added To House User Fee Bill
US FDA Gains Budget Increase In FY 2017… And Not Through Fees
Gottlieb's Confirmation: He's Willing To Disagree With Trump, Sec. Price
Trump's Budget Outline Threatens User Fee Agreements
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Trump Slams FDA Regulations In Joint Session Of Congress





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts